Pharmacokinetic problems in peritoneal drug administration: tissue penetration and surface exposure.
about
Peritoneal inflammation - A microenvironment for Epithelial Ovarian Cancer (EOC)Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with Low-Dose Cisplatin and Doxorubicin in Gastric Peritoneal Metastasis.Systematic review of pressurized intraperitoneal aerosol chemotherapy for the treatment of advanced peritoneal carcinomatosisPrognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: a Gynecologic Oncology Group study.Selective suppression of excessive GluN2C expression rescues early epilepsy in a tuberous sclerosis murine model.Using pharmacologic data to plan clinical treatments for patients with peritoneal surface malignancy.Intraoperative radiotherapy electron boost in advanced and recurrent epithelial ovarian carcinoma: a retrospective study.Intraperitoneal hyperthermic chemotherapy: experience at Baylor University Medical Center.Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival for patients with peritoneal carcinomatosis from colorectal cancer: a phase II study from a Chinese center.Hyperthermic intraperitoneal chemotherapy with melphalan: a summary of clinical and pharmacological data in 34 patients.Peritoneal carcinosis of ovarian origin.Pharmacokinetic and pharmacodynamic analysis of hyperthermic intraperitoneal oxaliplatin-induced neutropenia in subjects with peritoneal carcinomatosisA theoretical model for intraperitoneal delivery of cisplatin and the effect of hyperthermia on drug penetration distance.Monocyte/macrophage and T-cell infiltrates in peritoneum of patients with ovarian cancer or benign pelvic diseaseEmerging treatments for ovarian cancer.Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with cisplatin and doxorubicin in a woman with pseudomyxoma peritonei: A case report.Intraperitoneal clearance as a potential biomarker of cisplatin after intraperitoneal perioperative chemotherapy: a population pharmacokinetic studyHyperthermic intraoperative thoracoabdominal chemotherapy.Pharmacokinetics of the perioperative use of cancer chemotherapy in peritoneal surface malignancy patientsDoes hyperthermic intraoperative chemotherapy lead to improved outcomes in patients with ovarian cancer? A single center cohort study in 111 consecutive patientsNear-infrared fluorescent imaging of metastatic ovarian cancer using folate receptor-targeted high-density lipoprotein nanocarriers.Renal and hepatic toxicities after pressurized intraperitoneal aerosol chemotherapy (PIPAC)A phase I trial of oxaliplatin for intraperitoneal hyperthermic chemoperfusion for the treatment of peritoneal surface dissemination from colorectal and appendiceal cancers.Electromotive drug administration with mitomycin C for intravesical treatment of non-muscle invasive transitional cell carcinoma.Use of an anti-vascular endothelial growth factor antibody in a pharmacokinetic strategy to increase the efficacy of intraperitoneal chemotherapy.Outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface dissemination from ovarian neoplasmsOffice-based intraperitoneal chemotherapy for ovarian cancer.In Vivo Feasibility of Electrostatic Precipitation as an Adjunct to Pressurized Intraperitoneal Aerosol Chemotherapy (ePIPAC).Intraperitoneal chemotherapy of peritoneal carcinomatosis using pressurized aerosol as an alternative to liquid solution: first evidence for efficacy.A comparison of hematologic toxicity profiles after heated intraperitoneal chemotherapy with oxaliplatin and mitomycin C.Preclinical activity of melflufen (J1) in ovarian cancer.Intraperitoneal chemotherapy for peritoneal surface malignancy: experience with 1,000 patients.Impact of Pressurized Intraperitoneal Aerosol Chemotherapy on Quality of Life and Symptoms in Patients with Peritoneal Carcinomatosis: A Retrospective Cohort Study.Management of peritoneal carcinomatosis from colorectal cancer.Melphalan: a promising agent in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.Design of optimized hypoxia-activated prodrugs using pharmacokinetic/pharmacodynamic modeling.Drug development for intraperitoneal chemotherapy against peritoneal carcinomatosis from gastrointestinal cancer.Intraperitoneal chemotherapy in advanced epithelial ovarian cancer: a survey.Pressurized intraperitoneal chemotherapy (PIPAC) in women with gynecologic malignancies: a review.Tumour tissue transport after intraperitoneal anticancer drug delivery.
P2860
Q24804586-05A07610-E21C-44FF-A4B4-61F89B73F96EQ27313250-C1C91072-C15E-424A-942C-A40D6AB3C752Q29994639-F9B76C04-86DE-48C9-B17F-D0BAB394B2DAQ30359038-F4F52E4B-A687-44DE-9406-DB2AEBC5F35CQ30586288-40BA8497-A02B-4A85-921F-C130C5081906Q33416610-0BCD47E9-7564-4CDB-9FDF-B23790EEF955Q34046589-4366EDB1-8DB3-4CF6-8E56-B0F1CEB528ACQ34116747-7FFF1F32-18C4-493E-AD52-82B0D580900CQ34258723-D3323799-1FD3-4D43-BA7C-FE2AA039EA93Q34343492-C1D4C1C5-F226-4697-B6DF-0DDD3D12A7A4Q34391112-F3F557B4-04F9-4F59-9418-61F5081B468DQ34544598-DF58D4F4-B99A-43B1-9ADE-4E3457C0B0A7Q34770021-8957D3B9-BCCE-40D4-B3E6-FAF9013B3D89Q34997791-08742D8F-CC99-4BA3-8E99-3DD881107601Q35581174-483B3141-A995-4F05-8042-D031065E924DQ35614095-B090AFF5-6B7A-4360-8940-28F80B23FE59Q35739551-81EF5A5F-9DBC-44B5-B633-B54FCA7C60D1Q35978990-FCF4234D-ACE5-4A78-AE42-CC44F5E2DFFEQ36063487-FD1BDB14-213A-44C3-A632-652DBC7D557EQ36125424-58580F6D-AA06-482A-83F7-71FD0DF2970FQ36840545-3CF36A84-F6BC-47BA-9E90-A2C72D4FD343Q36909380-A5AD8E54-A48D-4C50-AB24-D57DBF14EE32Q36989557-60486420-A7F3-4ECA-BC7E-B071F7B82F70Q37039042-57EAFDDC-9D9F-4C06-99D4-AFF3FBBB9563Q37168526-C55A4425-7D79-4687-8C00-EC6CB9941D3DQ37284434-969A0802-903F-45A3-9051-FE2C7CE0C02FQ37477107-31EE1326-EDDB-458E-822D-31D0FB580C7EQ37492164-48F8FAFB-F661-4FC4-82AD-2A965C6162BCQ37594150-4BA10D13-EB16-4314-B40B-F6F4FA3DA6B0Q37597149-05AD59A9-8507-4BC9-AFE1-D9709496112AQ37644866-4C0B06B5-A1D3-4427-9431-E178B0022B15Q37662806-5F799AA2-19E6-43C0-81A3-340C2E4F74A8Q37683464-6CD13460-D7D0-4042-90BC-AC22EC6A8335Q37910396-53F9FE39-6FFF-43A6-A972-663D593F40BAQ38166245-AC9D7E02-7D1D-4283-AB7B-F3E9557E0BDDQ38177279-F5F22EC0-48AC-4A1F-B1B8-73D4CF6F1A23Q38183786-DF988AE3-5763-4A54-9BCB-53DA27462D35Q38213258-4B30F078-8016-41FF-AAE1-50C4A53FEC90Q38253577-992AF722-7983-422C-B476-0D98968B249EQ38679465-DD59DA40-1A5F-4BF9-8EE0-259CB965AD49
P2860
Pharmacokinetic problems in peritoneal drug administration: tissue penetration and surface exposure.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Pharmacokinetic problems in pe ...... etration and surface exposure.
@en
type
label
Pharmacokinetic problems in pe ...... etration and surface exposure.
@en
prefLabel
Pharmacokinetic problems in pe ...... etration and surface exposure.
@en
P2860
P356
P1476
Pharmacokinetic problems in pe ...... etration and surface exposure.
@en
P2093
Dedrick RL
Flessner MF
P2860
P304
P356
10.1093/JNCI/89.7.480
P407
P577
1997-04-01T00:00:00Z